Medicare Enrolled
Dr. Jeff Marshick, D.O.
Pulmonary Disease · Clarkston, MI
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Marshick from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Marshick?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Marshick
Dr. Jeff Marshick is a pulmonary disease specialist in Clarkston, MI, with 19 years of NPI registration. Based on federal Medicare data, Dr. Marshick performed 1,019 Medicare services across 804 unique beneficiaries.
Between the years covered by Open Payments, Dr. Marshick received a total of $15,309 from 55 pharmaceutical and/or device companies across 837 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Marshick is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 34% volume in MI
$15,309 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,019
Medicare services
Top 34% in MI for pulmonary disease
804
Unique beneficiaries
$69
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~54 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
296 | $84 | $120 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
212 | $61 | $85 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
154 | $40 | $75 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
93 | $126 | $185 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
48 | $43 | $100 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
48 | $105 | $185 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
47 | $44 | $100 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
40 | $66 | $100 |
| Expiratory airflow and volume test A test that measures the amount of air you can exhale and the speed at which you can breathe it out. It evaluates lung function by assessing expiratory airflow and volume. |
39 | $21 | $90 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
31 | $29 | $125 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
11 | $132 | $165 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$15,309
Total received (2018-2024)
Avg $2,187/year across 7 years
Top 7% in MI for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
55
Companies
837
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,210 (99.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$99 (0.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,331
2023
$2,669
2022
$2,116
2021
$2,123
2020
$1,852
2019
$2,296
2018
$1,922
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Boehringer Ingelheim Pharmaceuticals, Inc.
$426
HARMONY BIOSCIENCES LLC
$326
GlaxoSmithKline, LLC.
$275
AstraZeneca Pharmaceuticals LP
$221
Takeda Pharmaceuticals U.S.A., Inc.
$195
Mylan Specialty L.P.
$128
Regeneron Healthcare Solutions, Inc.
$92
GENZYME CORPORATION
$86
Azurity Pharmaceuticals, Inc.
$82
JAZZ PHARMACEUTICALS INC.
$72
Grifols USA, LLC
$62
Baxter Healthcare
$46
ANI Pharmaceuticals, Inc.
$44
Actelion Pharmaceuticals US, Inc.
$40
Inspire Medical Systems, Inc.
$33
Pharming Healthcare, Inc.
$33
Insmed, Inc.
$26
Axsome Therapeutics, Inc.
$25
Itamar Medical Inc
$25
Avadel CNS Pharmaceuticals, LLC
$25
Amgen Inc.
$23
Merck Sharp & Dohme LLC
$23
Pulmonx Corporation
$22
Top 3 companies account for 44.1% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$2,459
Boehringer Ingelheim Pharmaceuticals, Inc.
$2,059
GlaxoSmithKline, LLC.
$2,003
Takeda Pharmaceuticals U.S.A., Inc.
$897
Mylan Specialty L.P.
$867
Grifols USA, LLC
$619
Harmony Biosciences LLC
$510
JAZZ PHARMACEUTICALS INC.
$470
Regeneron Healthcare Solutions, Inc.
$449
Sunovion Pharmaceuticals Inc.
$419
GENZYME CORPORATION
$401
HARMONY BIOSCIENCES LLC
$372
Jazz Pharmaceuticals Inc.
$280
United Therapeutics Corporation
$257
Philips Electronics North America Corporation
$203
Genentech USA, Inc.
$186
Circassia Pharmaceuticals Inc
$177
Actelion Pharmaceuticals US, Inc.
$170
Shire North American Group Inc
$158
Teva Pharmaceuticals USA, Inc.
$157
Electromed, Inc.
$151
Alexion Pharmaceuticals, Inc.
$144
Mallinckrodt Hospital Products Inc.
$142
Mallinckrodt LLC
$113
Mallinckrodt Enterprises LLC
$112
Merck Sharp & Dohme LLC
$105
Amgen Inc.
$101
CSL Behring
$99
Axsome Therapeutics, Inc.
$99
ANI Pharmaceuticals, Inc.
$99
Insmed, Inc.
$96
Pulmonx Corporation
$82
Azurity Pharmaceuticals, Inc.
$82
Advanced Respiratory, Inc
$76
ARBOR PHARMACEUTICALS, INC.
$68
Novartis Pharmaceuticals Corporation
$60
Inspire Medical Systems, Inc.
$57
Arbor Pharmaceuticals, Inc.
$57
ABBVIE INC.
$55
Avadel CNS Pharmaceuticals, LLC
$48
Baxter Healthcare
$46
Inogen, Inc.
$43
Pharming Healthcare, Inc.
$33
Resmed Corp
$28
Itamar Medical Inc
$25
Paratek Pharmaceuticals, Inc.
$22
Hikma Pharmaceuticals USA
$20
Cumberland Pharmaceuticals, Inc.
$20
Nabriva Therapeutics, plc
$20
SANOFI-AVENTIS U.S. LLC
$19
La Jolla Pharmaceutical Company
$18
Covis Pharma GmBH
$17
PFIZER INC.
$15
E.R. Squibb & Sons, L.L.C.
$14
Gilead Sciences, Inc.
$12
Top 3 companies account for 42.6% of all-time payments
Associated products mentioned in payments ›
(7999) SRC Und · (8874) inCourage · ACTHAR · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · AirDuo Digihaler · Andexxa · Arikayce · Astral · BEVESPI AEROSPHERE · BREO · BREZTRI · BREZTRI AEROSPHERE · BRILINTA · BROVANA · CHARTIS CATHETER · CINQAIR · DUAKLIR PRESSAIR · DUPIXENT · DUPIXENT DUPILUMAB INJECTION · Disposable Vest · ELIQUIS · Esbriet · FARXIGA · FASENRA · GIAPREZA · GLASSIA · HORIZANT · HYQVIA · Hillrom - Vest System Model 105 Home Care · Horizant · INOGEN · INSPIRE · InogenOne · JANUVIA · KEYTRUDA · LONHALA MAGNAIR · LUMRYZ · NIOX VERO · NUCALA · NUZYRA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · PAXLOVID · PURIFIED CORTROPHIN GEL · Perforomist · ProAir Digihaler · Prolastin-C · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · RUCONEST · Ryaltris · SMARTVEST · SOLIRIS · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · Sunosi · TAGRISSO · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Monarch Airway Clearance System · The Vest System Model 105 Home Care · ULTOMIRIS · UTIBRON · UTIBRON NEOHALER · Ultomiris · Utibron · VERQUVO · Vibativ · WAKIX · Wakix · WatchPATONE · Wellcentive Undiv · XOLAIR · XYREM · XYWAV · Xenleta · Xolair · Xyrem · YUPELRI · Yupelri · ZERBAXA · Zemaira
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians. Total industry engagement is in the top 7% for pulmonary disease in MI.
Geographic Context
Pulmonary diseases within 10 mi
72
Per 100K population
5.7
County median income
$95,296
Nearest hospital
MCLAREN OAKLAND
9.3 mi
9.3 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Marshick is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 7% of MI peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Marshick experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Marshick performed 296 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Marshick receive payments from pharmaceutical companies?
Yes. Dr. Marshick received a total of $15,309 from 55 companies across 837 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Marshick's costs compare to other pulmonary diseases in Clarkston?
Dr. Marshick's average Medicare payment per service is $69. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Marshick) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Clarkston
Browse pulmonary diseases in Clarkston ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in MI
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in MI
Which MI pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology